Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Bone cancer" to "[[Category:Bone sarcoma") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.<ref name="insert">[http://www.pharmgkb.org/clinical/16515283.pdf Busulfan (Myleran) package insert]</ref><ref>[[Media:Busulfan.pdf | Busulfan (Myleran) package insert (locally hosted backup)]]</ref> | Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.<ref name="insert">[http://www.pharmgkb.org/clinical/16515283.pdf Busulfan (Myleran) package insert]</ref><ref>[[Media:Busulfan.pdf | Busulfan (Myleran) package insert (locally hosted backup)]]</ref> | ||
| − | <br>Route: IV | + | <br>Route: IV, PO |
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| Line 10: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| − | *[[ | + | *[[Chronic lymphocytic leukemia (CLL/SLL)]] |
*[[CNS lymphoma]] | *[[CNS lymphoma]] | ||
| − | *[[ | + | *[[Ewing's sarcoma]] |
| + | *[[Autologous HSCT|Autologous HSCT conditioning regimens]] | ||
| + | *[[Allogeneic HSCT|Allogeneic HSCT conditioning regimens]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 20: | Line 20: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 6/26/1954: Initial FDA approval | * 6/26/1954: Initial FDA approval | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Busulfex, Myleran | ||
==References== | ==References== | ||
| Line 25: | Line 28: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Oral medications]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
| Line 31: | Line 34: | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| − | [[Category: | + | [[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]] |
[[Category:Central nervous system (CNS) lymphoma medications]] | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
| + | [[Category:Ewing's sarcoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
[[Category:Drugs FDA approved in 1954]] | [[Category:Drugs FDA approved in 1954]] | ||
Revision as of 13:42, 30 October 2017
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute promyelocytic leukemia
- Chronic lymphocytic leukemia (CLL/SLL)
- CNS lymphoma
- Ewing's sarcoma
- Autologous HSCT conditioning regimens
- Allogeneic HSCT conditioning regimens
Patient drug information
- Busulfan (Myleran) patient drug information (Chemocare)[3]
- Busulfan (Myleran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval
Also known as
- Brand names: Busulfex, Myleran
References
Categories:
- Drug index
- Oral medications
- Intravenous medications
- Alkylating agents
- Irritant chemotherapy
- Acute promyelocytic leukemia medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Central nervous system (CNS) lymphoma medications
- Ewing's sarcoma medications
- Transplant medications
- Drugs FDA approved in 1954